南财智讯1月29日电，开勒股份发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为770 万元—1000万元，预计同比扭亏；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-120万元—-60万元。业绩变动主要原因如下：报告期内，公司通过优化业务布局，全面提升整体盈 利能力。一方面公司拓展海外市场成效显现，HVLS风扇业务境外销售收入占比有所提升，产品整体毛 利率实现稳步增长，对整体利润水平产生积极贡献；另一方面公司持续优化运营管理，积极落实降本增 效举措，有效控制管理费用、销售费用等期间费用支出，进一步夯实了整体盈利基础。 ...

证券之星消息，截至2026年1月28日收盘，港通医疗(301515)报收于24.11元，下跌1.27%，换手率 2.67%，成交量1.75万手，成交额4243.07万元。 1月28日的资金流向数据方面，主力资金净流出158.4万元，占总成交额3.73%，游资资金净流出324.57 万元，占总成交额7.65%，散户资金净流入482.98万元，占总成交额11.38%。 近5日资金流向一览见下表： | 日期 | | | | | 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-28 | 24.11 | -1.27% | -158.40万 | -3.73% | -324.57万 | -7.65% | 482.98万 | 11.38% | | 2026-01-27 | 24.42 | -1.13% | -296.99万 | -4.92% | -119.54万 | -1.98% | 416.53万 | 6.90% | | 2026-01-26 | | ...

Group 1 - The company Kaili Co., Ltd. announced a change in its auditing firm for the fiscal year 2025, with Tianjian Accounting Firm (Special General Partnership) replacing the signing auditor Lv Yingqun with Zhu Dawei [2] - The new signing auditors will be Zhu Dawei and Guo Yunhua, who will continue to complete the financial statements and internal control audit for the fiscal year 2025 [2]

Group 1 - The company responded to an investor inquiry regarding the number of shareholders as of January 20, 2026, stating that the total number of shareholders will be 9,594 [1]

Group 1 - The core viewpoint of the article is that 港通医疗 (Kangtong Medical) has provided information regarding its shareholder count as of January 20, 2026, indicating a total of 9,594 shareholders [2] Group 2 - The company responded to an investor inquiry about the number of shareholders, confirming the total count [2] - The information was shared through an investor relations platform, highlighting the company's engagement with its investors [1]

Group 1 - The company has recently secured project orders in African countries such as Kenya, Tunisia, and Djibouti [1] - The company encourages investors to monitor announcements on designated media platforms for major information disclosures [1]

Group 1 - The core viewpoint of the article is that the company, 港通医疗 (301515.SZ), has successfully secured project orders in various African regions, including Kenya, Tunisia, and Djibouti [1] Group 2 - The company has been actively expanding its operations in Africa, indicating a strategic focus on international markets [1] - The recent project orders reflect the company's growth and potential in the healthcare sector within these emerging markets [1]

Core Viewpoint - As of January 21, 2026, Kangtong Medical (301515) reported a closing price of 24.51 yuan, experiencing a slight decline of 0.28% with a turnover rate of 3.8% and a trading volume of 24,900 hands, amounting to a transaction value of 61.21 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Kangtong Medical reported a main revenue of 344 million yuan, a year-on-year decrease of 30.06% [2] - The net profit attributable to shareholders was -10.21 million yuan, reflecting a year-on-year decline of 150.92% [2] - The net profit after deducting non-recurring items was -12.87 million yuan, down 176.82% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 79.12 million yuan, which is a year-on-year increase of 42.81% [2] - The single-quarter net profit attributable to shareholders was -1.80 million yuan, a year-on-year decrease of 138.94% [2] - The single-quarter net profit after deducting non-recurring items was -2.60 million yuan, down 182.34% year-on-year [2] - The company's debt ratio stood at 40.94%, with investment income of -0.18 million yuan and financial expenses of 0.54 million yuan, while the gross profit margin was 22.45% [2] Group 2: Capital Flow - On January 21, 2026, the net outflow of main funds was 9.66 million yuan, accounting for 15.77% of the total transaction value [1] - The net outflow of speculative funds was 1.18 million yuan, representing 1.93% of the total transaction value [1] - The net inflow of retail funds was 10.84 million yuan, making up 17.71% of the total transaction value [1]

Core Viewpoint - The company, Hongtong Medical, focuses on the research, design, manufacturing, integration, and operation services of medical gas equipment and clean equipment systems, primarily serving various medical institutions [1] Group 1 - The main business of the company includes medical gas equipment and systems, as well as medical clean equipment and systems [1] - The company actively seeks overseas market cooperation opportunities under the framework of the China-Europe procurement strategic cooperation agreement, with recent overseas projects mainly concentrated in Africa [1]

Group 1 - The core viewpoint of the article is that the company, 港通医疗, is actively seeking overseas market opportunities under the framework of the China-Europe procurement strategic cooperation agreement, with a focus on the Southeast Asian market and ongoing projects primarily in Africa [1] Group 2 - 港通医疗's main business includes the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as medical clean equipment and systems, primarily serving various medical institutions [1] - The company has received inquiries from investors regarding progress in expanding into the Southeast Asian market and whether any orders have been secured [1]